Tag: Wegovy

Helmsley Charitable Trust Awards $3 Million Grant to Research Epithelial Healing in Crohn’s disease

sarah JonasResearch Results

he Helmsley Charitable Trust has awarded a grant of $3,035,566 to support groundbreaking research on Crohn’s disease, to be led by a collaborative team of leading researchers across three institutions. Louis J. Cohen, MD, Assistant Professor of Medicine (Gastroenterology) at the Icahn School of Medicine at Mount Sinai; Parakkal Deepak, MD, Associate Professor of Medicine (Gastroenterology), Washington University School of Medicine; and Andres J. Yarur, MD, Associate Professor of Medicine (Gastroenterology), Cedars-Sinai Medical Center, will serve as co-investigators.

New study shows popular diabetes and weight-loss drugs associated with lower risk for tobacco-use disorder

sarah JonasResearch Results

A new study by researchers at the Case Western Reserve School of Medicine reveals popular diabetes and weight-loss drugs are linked to a lower risk for tobacco-use disorder (TUD) in smokers with type 2 diabetes, compared with seven other anti-diabetes medications.

New Cedars-Sinai Study Investigates Shifting Trends in GLP-1RA Prescription

sarah JonasResearch Results

Investigators at Cedars-Sinai and other institutions conducted a nationwide, population-based study to identify trends in the use of glucagon-like peptide-1 receptor agonists (GLP-1RAs)—prescription medications sold under popular drug names like Ozempic and Wegovy—in the United States.

Retrospective Study Based on Electronic Health Records Finds Popular Diabetes and Weight-Loss Drugs Associated with Reduction in Incidence and Recurrence of Alcohol-Use Disorder by at Least Half

sarah JonasResearch Results

A new study by researchers at the Case Western Reserve University School of Medicine reveals that the popular diabetes and weight-loss drugs Wegovy and Ozempic are linked to reduced incidence and recurrence of alcohol abuse or dependence.

Should heart patients consider taking weight loss medications?

sarah Jonasblog

Over the last year, prescriptions for medications that can accelerate weight loss in people with diabetes, or without it, have skyrocketed. But how can these weight loss medications affect the heart? A preventive cardiologist shares how this shifting landscape might affect cardiovascular care and how he advises his patients.

Researchers at UC Irvine issue a warning that GLP-1RA’s may be dangerous for children

sarah JonasResearch Results

A team of clinicians, exercise scientists, pharmaceutical scholars, ethicists, and behavioral experts at the University of California, Irvine, outlined their concerns that the use of glucagon-like peptide-1 receptor agonists (GLP-1RA’s) to treat childhood obesity and type 2 diabetes may have unintended and adverse consequences for children’s health.

MEDIA ADVISORY: Cedars-Sinai Experts Available to Discuss Safety, Benefits of Using Medications to Lose Weight

sarah JonasExpert Pitch

The science is unclear on exactly why an increasingly popular new class of federally approved diabetes and obesity medications work, but they do know that they are effective at helping people lose weight.